Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly To Increase Investment In Chongqing

This article was originally published in PharmAsia News

Executive Summary

Eli Lilly officials recently visited Chongqing to seek market expansion. The firm has been forging a long-term collaboration with local medical institutions and colleges particularly in diabetes, where it will increase investment in areas such as public education, welfare services and academic exchange. It plans to add at least 800 employees in China and double the staff number in Chongqing to make it the top revenue generator in south-west China. Lilly is optimistic about Chongqing thanks to the latter's substantial strength in healthcare and talent. In addition, the city leads the push to implement urban-rural integrated medical insurance, which covers more patients, making it attractive to pharmaceutical companies. (Click here for more - Chinese Language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts